Chronic kidney disease–mineral and bone disorder as multidimensional bone–vascular risk framework: from biochemical control to risk-and context-guided care
- 1Department of Nephrology, First Affiliated Hospital of Henan University of Chinese Medicine
- 2Collaborative Innovation Center of Prevention and Treatment of Major Diseases by Chinese and Western Medicine
- 3Henan University of Chinese Medicine
Abstract
Chronic kidney disease-mineral and bone disorder (CKD-MBD) is a systemic complication that spans early CKD, dialysis and kidney transplantation. It is better understood not as an isolated disturbance of calcium and phosphate metabolism but as a multidimensional, dynamic syndrome in which mineral-endocrine dysregulation, skeletal remodeling, skeletal fragility and structural consequences, and vascular calcification interact to shape patient outcomes. This narrative review argues that management should move beyond the control of biochemical targets toward phenotype-informed, evidence-graded and outcome-oriented care organized around the bone–vascular axis. We first examine why surrogate-based management has under performed and then propose a working multidimensional framework based on four interrelated domains mineral and endocrine status, bone turnover and mineralization, skeletal fragility and structural consequences, vascular calcification and cardiovascular risk, and clinical modifiers and treatment context. We also grade the evidence behind the principal mechanisms and interventions, from phosphate retention, the FGF23-Klotho axis, vitamin D-PTH dysregulation, Wnt/β-catenin signaling and calciprotein particles to inflammation, gut dysbiosis and uremic toxins, distinguishing mechanistic plausibility from observational association, surrogate-endpoint trials and hard-endpoint benefit. We then match diagnostic tools, including bone turnover markers, DXA, HR-pQCT, 18F-NaF PET/CT, vascular calcification scoring, calcification propensity testing and bone biopsy, to the clinical decisions they are meant to inform, and reframe treatment of hyperphosphatemia, secondary hyperparathyroidism, CKD-associated osteoporosis and vascular calcification by multidimensional framework. The recurring theme is that biochemical improvement is not itself benefit: the field needs stratified, testable strategies anchored in fracture, cardiovascular events, hospitalization, mortality, quality of life and physical function.
Related
- Multi-omics proposes a complement-adhesion-stromal-vascular (CASVR) framework in chronic rhinosinusitis with nasal polyps
- Adipose-derived microvascular fragments: Functional microtissue units driving vascular integration and multidimensional tissue regeneration
- Ketoanalogues of Essential Amino Acids in Chronic Kidney Disease: From Biochemical Rationale to Conditions for Clinical Effectiveness
- Citrin Deficiency: Biochemical Mechanisms Underlying a Complex Hepatic Metabolic Disorder
- Multidimensional fidelity of the EPIC-Neck exercise programme for chronic non-specific neck pain: a UK feasibility trial process evaluation.
BibTeX
@article{chen2026chronic,
title = {{Chronic kidney disease–mineral and bone disorder as multidimensional bone–vascular risk framework: from biochemical control to risk-and context-guided care}},
author = {Guanting Chen and Tao Li and Kang Yang and Yaoxian Wang and Linqi Zhang},
journal = {Frontiers in Endocrinology},
year = {2026},
month = oct,
doi = {10.3389/fendo.2026.1954515},
url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.1954515/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Chronic kidney disease–mineral and bone disorder as multidimensional bone–vascular risk framework: from biochemical control to risk-and context-guided care
AU - Guanting Chen
AU - Tao Li
AU - Kang Yang
AU - Yaoxian Wang
AU - Linqi Zhang
PY - 2026
DA - 2026/10/29
JO - Frontiers in Endocrinology
DO - 10.3389/fendo.2026.1954515
UR - https://www.frontiersin.org/articles/10.3389/fendo.2026.1954515/full
AB - Chronic kidney disease-mineral and bone disorder (CKD-MBD) is a systemic complication that spans early CKD, dialysis and kidney transplantation. It is better understood not as an isolated disturbance of calcium and phosphate metabolism but as a multidimensional, dynamic syndrome in which mineral-endocrine dysregulation, skeletal remodeling, skeletal fragility and structural consequences, and vascular calcification interact to shape patient outcomes. This narrative review argues that management should move beyond the control of biochemical targets toward phenotype-informed, evidence-graded and outcome-oriented care organized around the bone–vascular axis. We first examine why surrogate-based management has under performed and then propose a working multidimensional framework based on four interrelated domains mineral and endocrine status, bone turnover and mineralization, skeletal fragility and structural consequences, vascular calcification and cardiovascular risk, and clinical modifiers and treatment context. We also grade the evidence behind the principal mechanisms and interventions, from phosphate retention, the FGF23-Klotho axis, vitamin D-PTH dysregulation, Wnt/β-catenin signaling and calciprotein particles to inflammation, gut dysbiosis and uremic toxins, distinguishing mechanistic plausibility from observational association, surrogate-endpoint trials and hard-endpoint benefit. We then match diagnostic tools, including bone turnover markers, DXA, HR-pQCT, 18F-NaF PET/CT, vascular calcification scoring, calcification propensity testing and bone biopsy, to the clinical decisions they are meant to inform, and reframe treatment of hyperphosphatemia, secondary hyperparathyroidism, CKD-associated osteoporosis and vascular calcification by multidimensional framework. The recurring theme is that biochemical improvement is not itself benefit: the field needs stratified, testable strategies anchored in fracture, cardiovascular events, hospitalization, mortality, quality of life and physical function.
SN - 1664-2392
ER -